Canaccord Genuity reaffirmed their buy rating on shares of Cryolife (NYSE:CRY) in a research note released on Friday. Canaccord Genuity currently has a $28.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $25.00.
Several other analysts have also issued reports on CRY. Northland Securities restated a buy rating and issued a $23.50 target price on shares of Cryolife in a research note on Monday, November 13th. Zacks Investment Research upgraded Cryolife from a sell rating to a hold rating in a research note on Tuesday, January 16th. Finally, ValuEngine lowered Cryolife from a hold rating to a sell rating in a research note on Wednesday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Cryolife has an average rating of Hold and a consensus price target of $25.83.
Shares of Cryolife (NYSE CRY) opened at $21.70 on Friday. The stock has a market capitalization of $726.03, a price-to-earnings ratio of 217.02 and a beta of 0.75. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.18 and a quick ratio of 4.90. Cryolife has a one year low of $14.02 and a one year high of $24.00.
In other news, Director C Elkins Ronald sold 2,000 shares of Cryolife stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $22.00, for a total value of $44,000.00. Following the completion of the transaction, the director now directly owns 97,849 shares in the company, valued at $2,152,678. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Cryolife by 4.9% in the fourth quarter. BlackRock Inc. now owns 4,344,104 shares of the medical equipment provider’s stock valued at $83,188,000 after purchasing an additional 204,843 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Cryolife by 1.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,994,820 shares of the medical equipment provider’s stock valued at $45,282,000 after purchasing an additional 34,599 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of Cryolife by 17.4% in the fourth quarter. Macquarie Group Ltd. now owns 1,888,879 shares of the medical equipment provider’s stock valued at $36,172,000 after purchasing an additional 279,595 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Cryolife by 6.6% in the second quarter. Vanguard Group Inc. now owns 1,658,646 shares of the medical equipment provider’s stock valued at $33,090,000 after purchasing an additional 102,540 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC grew its position in shares of Cryolife by 23.7% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 775,314 shares of the medical equipment provider’s stock valued at $14,847,000 after purchasing an additional 148,354 shares in the last quarter. Institutional investors own 73.99% of the company’s stock.
Cryolife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.